Insulin aspart faster-acting - Novo Nordisk

Drug Profile

Insulin aspart faster-acting - Novo Nordisk

Alternative Names: FIAsp; Fiasp; NN-1218; Ultra-fast-acting insulin aspart

Latest Information Update: 03 Apr 2017

Price : $50

At a glance

  • Originator Novo Nordisk
  • Class Antihyperglycaemics; Insulins; Pancreatic hormones; Peptides
  • Mechanism of Action Ornithine decarboxylase stimulants; Phosphokinase stimulants; Protein tyrosine kinase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Type 1 diabetes mellitus; Type 2 diabetes mellitus

Most Recent Events

  • 29 Mar 2017 Novo Nordisk resubmits NDA as class II resubmission to US FDA for Diabetes mellitus in USA
  • 27 Mar 2017 Novo Nordisk intends to file a class II re-submission to the US FDA for fast-acting insulin aspart for Diabetes mellitus
  • 03 Mar 2017 Launched for Type-1 diabetes mellitus (Combination therapy) in Canada (SC) - First Global Launch
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top